SVNS
NEUTRALSolvonis Therapeutics Announces Director Dealings
The specialty industrial machinery company has announced changes to its major shareholdings.
Solvonis Therapeutics
0.2660GBX
4.31%
Market Cap
24.57M
Volume
13.93M
20% of avg
P/E Ratio
EPS (TTM)
Beta
1.54
Day Range
0.2560p - 0.2560p
52 Week Range
0.1100p0.2660p0.3200p
0.2660p
Upcoming Events
SVNS
NEUTRALSolvonis Therapeutics Provides AGM Update
The biopharmaceutical company provides an update on its recent Annual General Meeting, highlighting shareholder support and the company's strategic positioning following a key acquisition.
SVNS
NEUTRALSolvonis Therapeutics Announces Director Shareholding Change
The specialty industrial machinery company has announced a change in director shareholdings.
SVNS
NEUTRALSolvonis Therapeutics Receives Initiation of Research Coverage
The biopharmaceutical company has received initiation of research coverage from Singer Capital Markets, providing an independent assessment of the business.
SVNS
NEUTRALSolvonis Therapeutics Announces Allowance of U.S. Patent for AI-Supported CNS Compounds
The biopharmaceutical company announces the allowance of a U.S. patent covering compounds from its AI-supported CNS discovery programme.
SVNS
NEUTRALSolvonis Therapeutics Launches AI-Driven CNS Drug Discovery Programme
The biopharmaceutical company is launching an AI-driven drug discovery programme to accelerate the identification and optimization of high-value development candidates within its CNS compound library.
SVNS
NEUTRALSolvonis Therapeutics Provides Update on SVN-SDN-014 Preclinical Program
The biopharmaceutical company provides an update on the progress of its preclinical program for a novel treatment targeting trauma-related mental health conditions.
SVNS
NEUTRALSolvonis Therapeutics Announces Annual General Meeting
The biopharmaceutical company has announced the details of its upcoming Annual General Meeting, to be held on 27 June 2025.
SVNS
NEUTRALSolvonis Therapeutics Appoints Renowned Neuroscientist as Chief Scientific Officer
The biopharmaceutical company has appointed a leading expert in brain science and psychiatric medicine to its management team as Chief Scientific Officer.
SVNS
NEUTRALSolvonis Therapeutics Announces Change in Shareholding
The biotechnology company has announced a change in its shareholding structure.